Parvin: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
Michal Harel (talk | contribs)
No edit summary
 
(11 intermediate revisions by 3 users not shown)
Line 1: Line 1:
<StructureSection load='2vzc' size='450' side='right' scene='Alpha-parvin/Cv/1' caption=''>
<StructureSection load='2vzc' size='450' side='right' scene='Alpha-parvin/Cv/1' caption='Human C-terminal domain of α-parvin complex with MPD, glycerol and TRS (PDB code [[2vzc]])'>
[[Alpha-parvin]]<ref>PMID: 11171322</ref>, also known as '''actopaxin'''<ref>PMID: 11134073</ref> or CH domain-containing integrin-linked kinase (ILK)-binding protein (CH-ILK-BP)<ref>PMID: 11331308</ref> is an adapter protein known to interact with a number of focal adhesion proteins leading to focal adhesion stabilisation. Knock-out analysis confirmed it to be essential for efficient directional cell migration during embryogenesis in mice<ref>PMID: 19798050</ref>. Spatially and temporarily regulated dynamic changes in the phosphorylation status of alpha-parvin at serines 4 and 8 and consequent changes in affinities towards its binding partners (icluding CdGAP, TESK1 and possibly others, e.g. ILK) may be responsible for 1) focal adhesion turnover (disassembly of old adhesions, assembly of new ones) and 2) actin cytoskeleton reorganization, two interrelated processes contributing to cell migration.<ref>PMID: 15353548</ref><ref>PMID: 15817463</ref><ref>PMID: 16860736</ref><ref>PMID: 15872073</ref>
== Function ==
'''Alpha-parvin'''<ref>PMID: 11171322</ref> (APAR), also known as '''actopaxin'''<ref>PMID: 11134073</ref> or '''CH domain-containing integrin-linked kinase (ILK)-binding protein''' (CH-ILK-BP)<ref>PMID: 11331308</ref> is an adapter protein known to interact with a number of focal adhesion proteins leading to focal adhesion stabilisation. Knock-out analysis confirmed it to be essential for efficient directional cell migration during embryogenesis in mice<ref>PMID: 19798050</ref>. Spatially and temporarily regulated dynamic changes in the phosphorylation status of alpha-parvin at serines 4 and 8 and consequent changes in affinities towards its binding partners (icluding CdGAP, TESK1 and possibly others, e.g. ILK) may be responsible for 1) focal adhesion turnover (disassembly of old adhesions, assembly of new ones) and 2) actin cytoskeleton reorganization, two interrelated processes contributing to cell migration.<ref>PMID: 15353548</ref><ref>PMID: 15817463</ref><ref>PMID: 16860736</ref><ref>PMID: 15872073</ref>


==Biological significance==
'''Beta-parvin''' (BPAR) is an actin-binding protein which contains calponin homo;ogy (CH) domains which bind actin filaments.  BPAR which has a role in cytoskeleton organization and cell adhesion.  BPAR inhibits integrin-linked kinase signaling and is downregulated in breast tumors<ref>PMID: 15467740</ref>
 
==Biological significance of APAR==


===Focal adhesions and cell migration===
===Focal adhesions and cell migration===
Line 15: Line 18:
Alpha-parvin possesses 6 putative proline-directed serine/threonine phosphorylation targets (residues 4, 8, 14, 16, 19, 61), of which serines 4 and 8 were shown to be the most important. Phosphorylation of alpha-parvin at serines 4 and 8 is correlated with the tightly regulated process of FA turnover during cell migration. Firstly, phosphorylation of these residues by cyclin B1/cdc2 is observed in the context of mitosis, whereby it contributes to FA disassembly required for cell-rounding prior to cell division, suggesting it may cause a similar effect during cell migration.<ref>PMID: 11931650</ref> Indeed, in migrating cells these residues are observed to be phosphorylated<ref>PMID: 15353548</ref>, likely as a result of MAP kinase<ref>PMID: 14636584</ref> and/or [[PI3K]]<ref>PMID: 12960424</ref>. Secondly, phosphomimetic mutations of serines 4 and 8 to aspartates result in faster migration and spreading, while mutations preventing phosphorylation impair these processes.<ref>PMID: 15353548</ref> Finally, as has already been mentioned in the introduction, knock-out mice phenotype (embryonic lethality due to severe cardiovascular defects) suggests alpha-parvin deficiency results in impaired directional migration of endothelial cells during embryonic development, heart development in particular.<ref>PMID: 19798050</ref> The macroscopic effects of alpha-parvin phosphorylation likely result from the altered affinity for its binding partners. So far it has been demonstrated that phosphorylation at serines 4 and 8 affects binding of alpha-parvin to TESK1 and CdGAP. When TESK1 is bound to alpha-parvin it is prevented from severing actin fibres. TESK1 is thought to be released from inhibition upon alpha-parvin phosphorylation and this can contribute to the decomposition of actin fibres and FA disassembly.<ref>PMID: 15817463</ref> CdGAP, on the other hand, is involved in the regulation of small GTPase signalling, which accounts for changes in cytoskeletal contractability during cell migration.<ref>PMID: 16860736</ref> Evidence suggesting that also the interaction with ILK is affected by phosphorylation is not strong<ref>PMID: 15872073</ref><ref>PMID: 12960424</ref>, but it is likely that this or yet other binding partners bind in the phosphorylation-dependent manner.
Alpha-parvin possesses 6 putative proline-directed serine/threonine phosphorylation targets (residues 4, 8, 14, 16, 19, 61), of which serines 4 and 8 were shown to be the most important. Phosphorylation of alpha-parvin at serines 4 and 8 is correlated with the tightly regulated process of FA turnover during cell migration. Firstly, phosphorylation of these residues by cyclin B1/cdc2 is observed in the context of mitosis, whereby it contributes to FA disassembly required for cell-rounding prior to cell division, suggesting it may cause a similar effect during cell migration.<ref>PMID: 11931650</ref> Indeed, in migrating cells these residues are observed to be phosphorylated<ref>PMID: 15353548</ref>, likely as a result of MAP kinase<ref>PMID: 14636584</ref> and/or [[PI3K]]<ref>PMID: 12960424</ref>. Secondly, phosphomimetic mutations of serines 4 and 8 to aspartates result in faster migration and spreading, while mutations preventing phosphorylation impair these processes.<ref>PMID: 15353548</ref> Finally, as has already been mentioned in the introduction, knock-out mice phenotype (embryonic lethality due to severe cardiovascular defects) suggests alpha-parvin deficiency results in impaired directional migration of endothelial cells during embryonic development, heart development in particular.<ref>PMID: 19798050</ref> The macroscopic effects of alpha-parvin phosphorylation likely result from the altered affinity for its binding partners. So far it has been demonstrated that phosphorylation at serines 4 and 8 affects binding of alpha-parvin to TESK1 and CdGAP. When TESK1 is bound to alpha-parvin it is prevented from severing actin fibres. TESK1 is thought to be released from inhibition upon alpha-parvin phosphorylation and this can contribute to the decomposition of actin fibres and FA disassembly.<ref>PMID: 15817463</ref> CdGAP, on the other hand, is involved in the regulation of small GTPase signalling, which accounts for changes in cytoskeletal contractability during cell migration.<ref>PMID: 16860736</ref> Evidence suggesting that also the interaction with ILK is affected by phosphorylation is not strong<ref>PMID: 15872073</ref><ref>PMID: 12960424</ref>, but it is likely that this or yet other binding partners bind in the phosphorylation-dependent manner.


==Structure and function==
==Structure and function of APAR==
===Domain composition===
===Domain composition===
Alpha-parvin's structure can be divided into four regions: 1) N-terminal flexible domain (residues 1-96), 2) N-terminal CH domain (97-200 according to SMART<ref>PMID: 9600884</ref>), 3) linker region (201-241) and 4) C-terminal CH domain (242-372 identified by limited subtilisin proteolysis<ref>PMID: 18940607</ref>). Most interactions of alpha-parvin are mapped to the C-terminal CH domain, but CdGAP and perhaps alphaPIX or other, yet unknown partners, interact with the N-terminal flexibile domain. This flexible domain seems to lack a well defined 3D structure and can therefore be classified as a putative [[Intrinsically Disordered Protein|intrinsically disordered]] region. The interactions of this regions with the binding partners are therefore likely to be characterized by relatively low affinity, but high affinity nonetheless.<ref>PMID: 19265676</ref> The abovementioned phosphorylation sites (serines 4 and 8) involved in focal adhesion regulation are located in this segment, which makes them so called disorder-enhanced phosphorylation sites.<ref>PMID: 14960716</ref><ref>PMID: 18388127</ref>
Alpha-parvin's structure can be divided into four regions: 1) N-terminal flexible domain (residues 1-96), 2) N-terminal CH domain (97-200 according to SMART<ref>PMID: 9600884</ref>), 3) linker region (201-241) and 4) C-terminal CH domain (242-372 identified by limited subtilisin proteolysis<ref>PMID: 18940607</ref>). Most interactions of alpha-parvin are mapped to the C-terminal CH domain, but CdGAP and perhaps alphaPIX or other, yet unknown partners, interact with the N-terminal flexibile domain. This flexible domain seems to lack a well defined 3D structure and can therefore be classified as a putative [[Intrinsically Disordered Protein|intrinsically disordered]] region. The interactions of this regions with the binding partners are therefore likely to be characterized by relatively low affinity, but high affinity nonetheless.<ref>PMID: 19265676</ref> The abovementioned phosphorylation sites (serines 4 and 8) involved in focal adhesion regulation are located in this segment, which makes them so called disorder-enhanced phosphorylation sites.<ref>PMID: 14960716</ref><ref>PMID: 18388127</ref>
Line 27: Line 30:
The <scene name='Alpha-parvin/Parvin/2'>scene on the right</scene> shows the superimposition of the three conformations that alpha-parvin adopts when bound to paxillin LD motifs, LD1 ([[2vzd]]), LD2 ([[2vzg]]) and LD4 ([[2vzi]]) respectively. These three LD motifs differ in sequence, but they are all helical. Surprisingly, the orientation of LD1 binding is reversed compared to that of LD2 and LD4. One of the LD motifs (LD1) is shown in the scene, represented by a blue helix. LD2 and LD4 are not shown, but they bind in the same location. As you can see, all three peptides, despite different sequences and different binding orientations, induce a very similar conformation of alpha-parvin, as represented by a very good alignment of the three alpha-parvin structures coloured differently. In particular, residues 248 to 264, which experience conformational change upon binding, are similar in all complexes with RMSD values of 0.28 Å (LD1 versus LD2), 0.23 Å (LD1 versus LD4), and 0.15 Å (LD2 versus LD4) in 16 equivalent C<sup>α</sup> positions.<ref>PMID: 18940607</ref>  
The <scene name='Alpha-parvin/Parvin/2'>scene on the right</scene> shows the superimposition of the three conformations that alpha-parvin adopts when bound to paxillin LD motifs, LD1 ([[2vzd]]), LD2 ([[2vzg]]) and LD4 ([[2vzi]]) respectively. These three LD motifs differ in sequence, but they are all helical. Surprisingly, the orientation of LD1 binding is reversed compared to that of LD2 and LD4. One of the LD motifs (LD1) is shown in the scene, represented by a blue helix. LD2 and LD4 are not shown, but they bind in the same location. As you can see, all three peptides, despite different sequences and different binding orientations, induce a very similar conformation of alpha-parvin, as represented by a very good alignment of the three alpha-parvin structures coloured differently. In particular, residues 248 to 264, which experience conformational change upon binding, are similar in all complexes with RMSD values of 0.28 Å (LD1 versus LD2), 0.23 Å (LD1 versus LD4), and 0.15 Å (LD2 versus LD4) in 16 equivalent C<sup>α</sup> positions.<ref>PMID: 18940607</ref>  


When you <scene name='Alpha-parvin/Parvin/5'>align</scene> the structure of one of the <font color='DimGrey'>alpha-parvin-LD</font> complexes, say the one with LD1 peptide bound, and the structure of <font color='brown'>alpha-parvin on its own (apo)</font>, you also get a good overall overlap (disregarding the long loop between helices αC and αE which, as was said before, is relatively flexible), but you can see that the <scene name='Alpha-parvin/Parvin/6'>vicinity of the binding site</scene> has slightly altered conformation. In particular, the angle between the <Structure load='3kmw' size='340' scene='Alpha-parvin/Ilk_parvin/1' frame='true' align='left' caption='Kinase domain of ILK/C-terminal CH domain of alpha-parvin core complex ([[3kmw]])'/>N-linker helix and αA widens by around 15° and the N-linker helix rotates.<ref>PMID: 18940607</ref> In this paragraph the binding of paxillin to the isolated C-terminal CH domain was described. However, the NMR measurements in solution confirmed that the rest of alpha-parvin molecule makes little energetic contribution to the binding. The pictue is not complete, though, since it is possible that the conformational alterations induced by LD binding in the N-terminal part of the C-terminal CH domain are somehow propagated to the nearby linker region and thus the rest of the molecule, possible affecting the behaviour of alpha-parvin towards other binding partners.
When you <scene name='Alpha-parvin/Parvin/5'>align</scene> the structure of one of the <font color='DimGrey'>alpha-parvin-LD</font> complexes, say the one with LD1 peptide bound, and the structure of <font color='brown'>alpha-parvin on its own (apo)</font>, you also get a good overall overlap (disregarding the long loop between helices αC and αE which, as was said before, is relatively flexible), but you can see that the <scene name='Alpha-parvin/Parvin/6'>vicinity of the binding site</scene> has slightly altered conformation. In particular, the angle between the N-linker helix and αA widens by around 15° and the N-linker helix rotates.<ref>PMID: 18940607</ref> In this paragraph the binding of paxillin to the isolated C-terminal CH domain was described. However, the NMR measurements in solution confirmed that the rest of alpha-parvin molecule makes little energetic contribution to the binding. The pictue is not complete, though, since it is possible that the conformational alterations induced by LD binding in the N-terminal part of the C-terminal CH domain are somehow propagated to the nearby linker region and thus the rest of the molecule, possible affecting the behaviour of alpha-parvin towards other binding partners.


===ILK binding===
===ILK binding===
The <scene name='Alpha-parvin/Ilk_parvin/1'>scene on the left</scene> shows the complex ([[3kmw]]) of the kinase domain of integrin-linked kinase (ILK, red) bound to the C-terminal CH domain of alpha-parvin (blue). One can also see the molecule of ATP (green) and the space-fill representation of the magnesium atom (white). When we <scene name='Alpha-parvin/Ilk_parvin/2'>turn the structure</scene> so that the N-terminal helix (now orange) of the CH domain of alpha-parvin is pointing up, we can see that unlike paxillin LD motifs, ILK kinase domain does not bind to the N-terminal region of the CH domain, but rather near the <scene name='Alpha-parvin/Ilk_parvin/3'>long loop</scene> between helices αC and αE. Other parts of the CH domain are also involved in binding, leading to a high interface area (around 1900 Å<sup>2</sup>) characteristic of high-affinity complexes.<ref>PMID:20005845</ref> Interestingly, ILK, which was recently proved to lack kinase activity<ref>PMID:20005845</ref><ref>PMID: 20033063</ref>, binds alpha-parvin analogously to the way in which kinases bind their substrates, i.e. with its pseudoactive site. The binding is not dependent on the presence of ATP. On the ILK's side the binding is mediated primarily by <scene name='Alpha-parvin/Ilk_parvin/6'>one of the helices</scene> (αG) and a <scene name='Alpha-parvin/Ilk_parvin/5'>part of the activation loop</scene>. The complex formation is particularly dependent on <scene name='Alpha-parvin/Ilk_parvin/7'>methionine 402 and lysine 403</scene> in αG of ILK - if these two residues are mutated to alanines, the complex formation is completely abolished. These residues are involved in many interactions with alpha-parvin (one of them, a hydrogen bond to asparagine 280, is shown) or water molecules (one of them shown as a pink dot).
The <scene name='Alpha-parvin/Ilk_parvin/1'>scene on the left</scene> shows the complex ([[3kmw]]) of the kinase domain of integrin-linked kinase (ILK, red) bound to the C-terminal CH domain of alpha-parvin (blue). One can also see the molecule of ATP (green) and the space-fill representation of the magnesium atom (white). When we <scene name='Alpha-parvin/Ilk_parvin/2'>turn the structure</scene> so that the N-terminal helix (now orange) of the CH domain of alpha-parvin is pointing up, we can see that unlike paxillin LD motifs, ILK kinase domain does not bind to the N-terminal region of the CH domain, but rather near the <scene name='Alpha-parvin/Ilk_parvin/3'>long loop</scene> between helices αC and αE. Other parts of the CH domain are also involved in binding, leading to a high interface area (around 1900 Å<sup>2</sup>) characteristic of high-affinity complexes.<ref>PMID:20005845</ref> Interestingly, ILK, which was recently proved to lack kinase activity<ref>PMID:20005845</ref><ref>PMID: 20033063</ref>, binds alpha-parvin analogously to the way in which kinases bind their substrates, i.e. with its pseudoactive site. The binding is not dependent on the presence of ATP. On the ILK's side the binding is mediated primarily by <scene name='Alpha-parvin/Ilk_parvin/6'>one of the helices</scene> (αG) and a <scene name='Alpha-parvin/Ilk_parvin/5'>part of the activation loop</scene>. The complex formation is particularly dependent on <scene name='Alpha-parvin/Ilk_parvin/7'>methionine 402 and lysine 403</scene> in αG of ILK - if these two residues are mutated to alanines, the complex formation is completely abolished. These residues are involved in many interactions with alpha-parvin (one of them, a hydrogen bond to asparagine 280, is shown) or water molecules (one of them shown as a pink dot).


==3D structures of Alpha-parvin==
==3D structures of parvin==
 
[[Parvin 3D structures]]
Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}}
 
[[3kmu]] - hAPAR + integrin-linked kinase pseudokinase domain – human<br />
[[3rep]], [[3kmw]] – hAPAR + integrin-linked kinase pseudokinase domain + ATP<br />
[[2vzc]] – hAPAR calponin homology domain<br />
[[2vzd]], [[2vzg]], [[2vzi]] - hAPAR calponin homology domain + paxillin motif<br />
[[2k2r]] - hAPAR calponin homology domain + paxillin LD1 motif - NMR


</StructureSection>


==References==
==References==
<references />
<references />
[[Category:Topic Page]]
[[Category:Topic Page]]

Latest revision as of 07:36, 7 March 2019

Human C-terminal domain ofα-parvin complex with MPD, glycerol and TRS (PDB code 2vzc)

Drag the structure with the mouse to rotate

References